Schrödinger, Inc. filings document an operating company with Software and Drug Discovery segments, including reported financial results, software revenue metrics, and disclosures about its computational platform for molecular discovery. Form 8-K reports furnish results of operations and material events, while other filings address clinical or regulatory disclosures and capital-structure matters.
Proxy and governance filings cover director elections, executive compensation, equity awards and shareholder voting matters. The record also includes disclosures about officer appointments, separation arrangements, compensatory matters, and voting rights for common stock and limited common stock, tying governance and ownership topics to the company's public-company structure.
Schrodinger, Inc. (SDGR) reported third-quarter revenue of $64.5 million, compared with $54.3 million a year earlier. Drug discovery revenue was $24.2 million versus $13.0 million, while software products and services revenue was $38.2 million versus $35.9 million. Third-quarter net loss was $37.7 million, compared with $32.8 million. For the first nine months, revenue was $182.0 million versus $168.6 million and net loss was $91.8 million versus $135.8 million.
Net cash used in operating activities was $96.5 million in the first nine months, compared with $30.0 million provided a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled $373.4 million as of September 30, 2026. Remaining performance obligations were $186.7 million, with approximately 62% expected to be recognized in the next 12 months. In September 2026, Schrodinger and Novartis amended their research collaboration to replace certain programs with two new programs; Schrodinger is eligible for up to $1.424 billion in total milestone payments under the amended agreement.
Schrödinger, Inc. (SDGR) reported third-quarter 2026 revenue of $64.5 million, up 19% year over year, and annual contract value (ACV) of $44.7 million, up 17%. Drug discovery revenue was $24.2 million versus $13.0 million, primarily reflecting a milestone payment from Structure Therapeutics; software revenue was $38.2 million, up 6%. Net loss was $37.7 million versus $32.8 million, while operating expenses fell 13% to $64.4 million. Cash, cash equivalents, restricted cash and marketable securities were $373 million.
The company raised full-year 2026 ACV guidance to $222 million–$232 million from $218 million–$228 million, and drug discovery revenue guidance to $75 million–$85 million from $65 million–$75 million; operating expenses are expected to be less than 2025. For the nine months ended September 30, 2026, net cash used in operating activities was $96.5 million, compared with $30.0 million provided in 2025.
Schrödinger said it has not initiated a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities to continue the program’s development. It contributed two early-stage programs to Tectora in exchange for an equity stake and eligibility for future milestones and royalties, in connection with Tectora’s $55 million Series A financing.
Schrodinger, Inc. (SDGR) reported that executive Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships, exercised options for 31,599 shares of common stock at an exercise price of $4.34 per share on September 17, 2026, from a fully vested option granted on November 29, 2018. On the same day, she sold 10,000 shares at $28.00 and 21,599 shares at $30.00, in total selling the 31,599 shares acquired, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025; a remaining option position of 11,599 shares is reported, and her equity holdings include 63,545 unvested RSUs.
Schrodinger, Inc. (SDGR) is the issuer of common stock that an officer, Karen Olufunmilyo Akinsanya-Akiwumi, has notified under Rule 144 an intention to sell. The notice covers 31,599 shares of common stock, with an approximate aggregate market value of $756,164.07, to be sold through Morgan Stanley Smith Barney LLC. The proposed sale date is September 17, 2026, and the shares are to be issued via an exercise of stock options and sold for cash on NASDAQ.
Schrödinger, Inc. develops a physics-based computational platform used for drug discovery and materials science and licenses related software while pursuing proprietary and partnered drug programs. For the three months ended June 30, 2026, it generated $58,889 (in thousands) of revenue, up from $54,759 (in thousands) a year earlier. Software products and services contributed $32,544 (in thousands), drug discovery $22,986 (in thousands), and contribution revenue $3,359 (in thousands).
Gross profit was $32,432 (in thousands), with an operating loss of $41,547 (in thousands). A $45,868 (in thousands) gain from equity investments and $3,026 (in thousands) of other income produced net income of $5,975 (in thousands), versus a net loss of $43,173 (in thousands) in the prior-year quarter. For the first six months of 2026, revenue was $117,476 (in thousands) and the net loss was $54,051 (in thousands).
As of June 30, 2026, cash, cash equivalents, restricted cash, and marketable securities totaled $418,802, with total assets of $640,394 (in thousands) and stockholders’ equity of $328,956 (in thousands). Deferred revenue was $149,925, and remaining performance obligations were $189,066, about 63% expected to be recognized within 12 months. Significant collaboration agreements with Bristol Myers Squibb and Novartis include potential milestones of $482.0 million and $2.272 billion, respectively, recognized over time as performance obligations are met.
Schrödinger, Inc. reported Q2 2026 total revenue of $58.9 million, an 8% increase from Q2 2025, with ACV of $29.6 million, a 27% increase and $208 million on a trailing four-quarter basis. Drug discovery revenue rose to $23.0 million, supported by a $10 million collaboration milestone related to the Ajax Therapeutics acquisition, while software revenue declined 10% to $32.5 million as the company accelerated its transition to hosted licensing.
Software gross margin was 71% and operating expenses fell 6% to $74.0 million. Other income was $48.9 million, primarily from a gain associated with Eli Lilly and Company’s acquisition of Ajax Therapeutics, resulting in net income of $6.0 million compared with a $43.2 million net loss a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled $418.8 million.
For 2026, Schrödinger expects ACV of $218–$228 million, representing 10–15% growth, and raised drug discovery revenue guidance to $65–$75 million. The company launched its agentic AI co-scientist Bunsen, expanded a strategic software agreement with Bristol Myers Squibb, signed a global discovery collaboration with Simcere, and highlighted peer-reviewed research validating its physics-based platform.
Schrodinger, Inc. EVP & CFO Rachit Jain reported selling 875 shares of common stock on July 16, 2026, at a weighted average price of $15.597 per share. The broker-assisted sale was executed under a Rule 10b5-1 durable automatic instruction to satisfy withholding tax liability from vested RSUs and is not a discretionary trade. Following the sale, Jain directly holds 50,877 shares, which include 43,154 unvested RSUs.
Rachit Jain plans to sell SDGR common stock through Fidelity Brokerage Services LLC. The planned transaction covers 875 shares of common stock on NASDAQ on 07/16/2026, with an aggregate market value of $13,647.11. These shares arise from Restricted Stock Vesting dated 07/15/2026 and are categorized as compensation.
The disclosure also notes a prior sale during the last three months of 844 shares of common stock on 04/16/2026 for an aggregate sale price of $10,758.47.
Schrodinger, Inc. director Richard Friesner reported estate-planning transfers involving Schrodinger common stock. Two bona fide gifts totaling 1,358,746 shares were made on June 26, 2026 through entities described as the RF 2018 GRAT and a grantor retained annuity trust, with shares now held by the RF 2018 Family Trust and similar vehicles rather than sold on the market.
Following these changes, Friesner is shown as directly owning 705,917 shares of common stock, which include 8,141 unvested RSUs and 2,335 shares transferred from the RF 2018 GRAT. An additional 28,328 shares are reported as indirectly owned through his spouse. Shares held by the Family Trust, where his spouse is a trustee and his children are beneficiaries, are reported with a disclaimer of beneficial ownership except for any pecuniary interest.